Trials / Terminated
TerminatedNCT05176080
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
Study to Evaluate the Efficacy and Safety of Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study was to evaluate the efficacy and safety of treatment with famitinib plus SHR6390 and endocrine therapy for hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative advanced breast cancer.
Detailed description
This study would enroll patients with hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative advanced breast cancer, aimed to evaluate the efficacy and safety of treatment with famitinib combined with SHR6390 and endocrine therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famitinib | Famitinib orally, daily or every other day |
| DRUG | SHR6390 | SHR6390 orally, daily for 3 weeks followed by 1 week off |
| DRUG | Fulvestrant | Fulvestrant |
Timeline
- Start date
- 2021-12-08
- Primary completion
- 2024-07-03
- Completion
- 2024-07-03
- First posted
- 2022-01-04
- Last updated
- 2024-12-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05176080. Inclusion in this directory is not an endorsement.